Local Ventromedial Hypothalamus Glucopenia Triggers Counterregulatory Hormone Release
Overview
Authors
Affiliations
To test the hypothesis that nuclei of the ventromedial hypothalamus (VMH) play a key role in the detection of counterregulatory responses to hypoglycemia, we delivered the glucopenic agent 2-deoxyglucose via bilaterally placed microdialysis probes into the VMH of conscious, chronically catheterized rats. The goal was to produce cellular glucopenia localized to the VMH. The volume of brain tissue exposed to 2-deoxyglucose was determined by adding [3H]2-deoxyglucose to the dialysate; its distribution in cerebral tissue was almost exclusively limited to the VMH. Rats with microdialysis probes placed into the frontal lobes served as a control group. Local perfusion of 2-deoxyglucose (but not glucose) into the VMH caused a prompt twofold increase in plasma glucose in association with a striking elevation of plasma glucagon (3.5-fold), epinephrine (30-fold), and norepinephrine (3.5-fold). No effect was seen when 2-deoxyglucose was delivered into the frontal lobes. We conclude that glucopenia localized to the VMH triggers the release of counterregulatory hormones that defend against hypoglycemia. Thus, the neurons that sense glucopenia may be situated in the VMH.
Liu L, Huang Z, Zhang J, Wang M, Yue T, Wang W Nat Commun. 2024; 15(1):8632.
PMID: 39366937 PMC: 11452707. DOI: 10.1038/s41467-024-52815-3.
Intra-islet α-cell Gs signaling promotes glucagon release.
Liu L, El K, Dattaroy D, Barella L, Cui Y, Gray S Nat Commun. 2024; 15(1):5129.
PMID: 38879678 PMC: 11180188. DOI: 10.1038/s41467-024-49537-x.
Barahona M, Langlet F, Labouebe G, Croizier S, Picard A, Thorens B Sci Rep. 2022; 12(1):17717.
PMID: 36271117 PMC: 9587252. DOI: 10.1038/s41598-022-22489-2.
Remembrance of things past: The consequences of recurrent hypoglycaemia in diabetes.
McCrimmon R Diabet Med. 2022; 39(12):e14973.
PMID: 36251572 PMC: 10015985. DOI: 10.1111/dme.14973.
Antipsychotics impair regulation of glucose metabolism by central glucose.
Castellani L, Pereira S, Kowalchuk C, Asgariroozbehani R, Singh R, Wu S Mol Psychiatry. 2022; 27(11):4741-4753.
PMID: 36241692 DOI: 10.1038/s41380-022-01798-y.